BioCentury | Feb 8, 2010
Finance

Cancer immunotherapy mentor

...Biotechnology Corp. (NASDAQ:GNBT) as a proxy for its Antigen Express immunotherapeutic subsidiary. One private company, Quantum Immunologics Inc....
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP) Disease focus: Cancer Clinical status: Phase I/II Founded: 2008 by Charles Broes University collaborators: University of South Alabama...
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...future clinical trials of the immunotherapy. Companies and Institutions Mentioned Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. Quantum Immunologics Inc....
BioCentury | Jul 27, 2009
Clinical News

Dendritic cell vaccine: Phase I/II restarted

...site in May 2008, has been expanded to include multiple sites under a national IRB. Quantum Immunologics Inc....
BioCentury | Jul 20, 2009
Financial News

Quantum Immunologics completes venture financing

Quantum Immunologics Inc. , Tampa, Fla. Business: Cancer Date completed: 7/10/09 Type: Venture financing Raised: $2.2 million Investor: Mentor Capital WIR Staff cancer...
BioCentury | May 5, 2008
Clinical News

Anti-cancer immunotherapy: Phase I/II started

...immature laminin receptor protein, a universal cancer antigen expressed in all types of human cancer. Quantum Immunologics Inc....
Items per page:
1 - 6 of 6
BioCentury | Feb 8, 2010
Finance

Cancer immunotherapy mentor

...Biotechnology Corp. (NASDAQ:GNBT) as a proxy for its Antigen Express immunotherapeutic subsidiary. One private company, Quantum Immunologics Inc....
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP) Disease focus: Cancer Clinical status: Phase I/II Founded: 2008 by Charles Broes University collaborators: University of South Alabama...
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...future clinical trials of the immunotherapy. Companies and Institutions Mentioned Dendreon Corp. (NASDAQ:DNDN), Seattle, Wash. Quantum Immunologics Inc....
BioCentury | Jul 27, 2009
Clinical News

Dendritic cell vaccine: Phase I/II restarted

...site in May 2008, has been expanded to include multiple sites under a national IRB. Quantum Immunologics Inc....
BioCentury | Jul 20, 2009
Financial News

Quantum Immunologics completes venture financing

Quantum Immunologics Inc. , Tampa, Fla. Business: Cancer Date completed: 7/10/09 Type: Venture financing Raised: $2.2 million Investor: Mentor Capital WIR Staff cancer...
BioCentury | May 5, 2008
Clinical News

Anti-cancer immunotherapy: Phase I/II started

...immature laminin receptor protein, a universal cancer antigen expressed in all types of human cancer. Quantum Immunologics Inc....
Items per page:
1 - 6 of 6